MTOR and liver cancer: Notably, the simultaneous administration of the PI3K/mTOR dual inhibitor BEZ235 and L. rhamnosus HN001 demonstrated a consistent increase in the duration of survival of cardiac transplant recipients, while concurrently suppressing the progression of primary liver cancer.